electroCore, Inc. (NASDAQ:ECOR – Get Free Report) CFO Joshua Lev sold 3,000 shares of electroCore stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $9.36, for a total transaction of $28,080.00. Following the sale, the chief financial officer directly owned 84,889 shares in the company, valued at $794,561.04. The trade was a 3.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
electroCore Trading Down 1.9%
electroCore stock traded down $0.18 during trading hours on Tuesday, hitting $9.47. 109,294 shares of the stock traded hands, compared to its average volume of 88,973. electroCore, Inc. has a one year low of $4.41 and a one year high of $10.95. The firm’s 50-day moving average price is $7.74 and its two-hundred day moving average price is $7.21. The company has a market cap of $85.42 million, a PE ratio of -5.70 and a beta of 0.93.
electroCore (NASDAQ:ECOR – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.09. The firm had revenue of $9.45 million during the quarter, compared to analyst estimates of $9.49 million. electroCore had a negative return on equity of 1,956.38% and a negative net margin of 39.96%. On average, sell-side analysts expect that electroCore, Inc. will post -1.4 earnings per share for the current fiscal year.
Hedge Funds Weigh In On electroCore
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of electroCore in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $18.00.
Check Out Our Latest Report on ECOR
About electroCore
electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.
The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.
Further Reading
- Five stocks we like better than electroCore
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
